The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Development of a Potent Bcl-xLAntagonist Based on α-Helix Mimicry
Abstract
The rational design of low-molecular weight ligands that disrupt protein-protein interactions is still a challenging goal in medicinal chemistry. Our approach to this problem involves the design of molecular scaffolds that mimic the surface functionality projected along one face of an alpha-helix. Using a terphenyl scaffold, which in a staggered conformation closely reproduces the projection of functionality on the surface of an alpha-helix, we designed mimics of the pro-apoptotic alpha-helical Bak-peptide as inhibitors of the Bak/Bcl-xL interaction. This led to the development of a potent Bcl-xL antagonist (KD = 114 nM), whose binding affinity for Bcl-xL was assessed by a fluorescence polarization assay. To determine the binding site of the developed inhibitor we used docking studies and an HSQC-NMR experiment with 15N-labeled Bcl-xL protein. These studies suggest that the inhibitor is binding in the same hydrophobic cleft as the Bak- and Bad-peptides.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure of Bcl-x L -Bak Peptide Complex: Recognition Between Regulators of Apoptosis
Sattler, M., Liang, H., Nettesheim, D., Meadows, R. P., Harlan, J. E., Eberstadt, M., Yoon, H. S., Shuker, S. B., Chang, B. S., Minn, A. J., et al. (1997) · Science · doi:10.1126/science.275.5302.983 · Cited by 1,476
X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death
Muchmore, S. W., Sattler, M., Liang, H., Meadows, R. P., Harlan, J. E., Yoon, H. S., Nettesheim, D., Chang, B. S., Thompson, C. B., Wong, S.-L., et al. (1996) · Nature · doi:10.1038/381335a0 · Cited by 1,467
A Breathing Hybrid Organic–Inorganic Solid with Very Large Pores and High Magnetic Characteristics
Barthelet, K., Marrot, J., Riou, D., & Férey, G. (2002) · Angewandte Chemie International Edition · doi:10.1002/1521-3773(20020118)41:2<281::aid-anie281>3.0.co;2-y · Cited by 977
Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL
Degterev, A., Lugovskoy, A., Cardone, M., Mulley, B., Wagner, G., Mitchison, T., & Yuan, J. (2001) · Nature Cell Biology · doi:10.1038/35055085 · Cited by 550
A Protein-Counting Mechanism for Telomere Length Regulation in Yeast
Marcand, S., Gilson, E., & Shore, D. (1997) · Science · doi:10.1126/science.275.5302.986 · Cited by 524
PETROS, A. M., NETTESHEIM, D. G., WANG, Y., OLEJNICZAK, E. T., MEADOWS, R. P., MACK, J., SWIFT, K., MATAYOSHI, E. D., ZHANG, H., THOMPSON, C. B., et al. (2000) · Protein Science · doi:10.1017/s096183680000331x · Cited by 412
Orner, B. P., Ernst, J. T., & Hamilton, A. D. (2001) · Journal of the American Chemical Society · doi:10.1021/ja0025548 · Cited by 320
Self-citationStructure of mitochondrial creatine kinase
Fritz-Wolf, K., Schnyder, T., Wallimann, T., & Kabsch, W. (1996) · Nature · doi:10.1038/381341a0 · Cited by 294
Bad Is a BH3 Domain-Containing Protein That Forms an Inactivating Dimer with Bcl-X L
Kelekar, A., Chang, B. S., Harlan, J. E., Fesik, S. W., & Thompson, C. B. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.12.7040 · Cited by 274
Protein–protein interfaces: mimics and inhibitors
Cochran, A. G. (2001) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(01)00262-9 · Cited by 133
Cited by
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705
Promoting apoptosis as a strategy for cancer drug discovery
Fesik, S. W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1736 · Cited by 1,098
Bcl-2 family proteins and cancer
Yip, K. W., & Reed, J. C. (2008) · Oncogene · doi:10.1038/onc.2008.307 · Cited by 881
Metal-Free, Visible-Light-Mediated Direct C–H Arylation of Heteroarenes with Aryl Diazonium Salts
Hari, D. P., Schroll, P., & König, B. (2012) · Journal of the American Chemical Society · doi:10.1021/ja212099r · Cited by 798
Guichard, G., & Huc, I. (2011) · Chemical Communications · doi:10.1039/c1cc11137j · Cited by 769
Structural biology of the Bcl-2 family of proteins
Petros, A. M., Olejniczak, E. T., & Fesik, S. W. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2003.08.012 · Cited by 745
Inhibition of α-helix-mediated protein–protein interactions using designed molecules
Azzarito, V., Long, K., Murphy, N. S., & Wilson, A. J. (2013) · Nature Chemistry · doi:10.1038/nchem.1568 · Cited by 727
Pelay‐Gimeno, M., Glas, A., Koch, O., & Grossmann, T. N. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201412070 · Cited by 717
Shangary, S., & Wang, S. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094723 · Cited by 623
BCL-2 family antagonists for cancer therapy
Lessene, G., Czabotar, P. E., & Colman, P. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2658 · Cited by 621
Discovery and Cocrystal Structure of Benzodiazepinedione HDM2 Antagonists That Activate p53 in Cells
Grasberger, B. L., Lu, T., Schubert, C., Parks, D. J., Carver, T. E., Koblish, H. K., Cummings, M. D., LaFrance, L. V., Milkiewicz, K. L., Calvo, R. R., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049137g · Cited by 432
Apoptosis in the development and treatment of cancer
Gerl, R. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh283 · Cited by 385
New Modalities for Challenging Targets in Drug Discovery
Valeur, E., Guéret, S. M., Adihou, H., Gopalakrishnan, R., Lemurell, M., Waldmann, H., Grossmann, T. N., & Plowright, A. T. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201611914 · Cited by 382
Kitada, S., Leone, M., Sareth, S., Zhai, D., Reed, J. C., & Pellecchia, M. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030190z · Cited by 379
Single Turn Peptide Alpha Helices with Exceptional Stability in Water
Shepherd, N. E., Hoang, H. N., Abbenante, G., & Fairlie, D. P. (2005) · Journal of the American Chemical Society · doi:10.1021/ja0456003 · Cited by 326
Structural and biological mimicry of protein surface recognition by α/β-peptide foldamers
Horne, W. S., Johnson, L. M., Ketas, T. J., Klasse, P. J., Lu, M., Moore, J. P., & Gellman, S. H. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902663106 · Cited by 275
Ernst, J. T., Becerril, J., Park, H. S., Yin, H., & Hamilton, A. D. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200390154 · Cited by 273
Self-citationTerphenyl‐Based Helical Mimetics That Disrupt the p53/HDM2 Interaction
Yin, H., Lee, G., Park, H. S., Payne, G. A., Rodriguez, J. M., Sebti, S. M., & Hamilton, A. D. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200462316 · Cited by 255
Self-citationRational Design of Proteolytically Stable, Cell-Permeable Peptide-Based Selective Mcl-1 Inhibitors
Muppidi, A., Doi, K., Edwardraja, S., Drake, E. J., Gulick, A. M., Wang, H.-G., & Lin, Q. (2012) · Journal of the American Chemical Society · doi:10.1021/ja306864v · Cited by 156
Small molecule modulators of protein-protein interactions: selected case studies
Aeluri, M., Chamakuri, S., Dasari, B., Guduru, S. K. R., Jimmidi, R., Jogula, S., & Arya, P. (2014) · Chemical Reviews · doi:10.1021/cr4004049 · Cited by 79
Plucking the high hanging fruit: A systematic approach for targeting protein–protein interactions
Raj, M., Bullock, B. N., & Arora, P. S. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.11.023 · Cited by 66
Metadata
- Authors
- Kutzki, O., Park, H. S., Ernst, J. T., Orner, B. P., Yin, H., & Hamilton, A. D.
- Venue
- Journal of the American Chemical Society
- Publisher
- American Chemical Society (ACS)
- Published
- 2002-09-12
- Volume
- 124
- Issue
- 40
- Pages
- 11838-11839
- ISSN
- 0002-7863 (ISSN-L)
- 1520-5126
- OpenAlex
- W2018221677
- Cited by
- 253
- References
- 12
- FWCI
- 6.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.